主要文件

查看所有文档

Y0000271

奥沙利铂

Name: 奥沙利铂
Brand: SIAL

European Pharmacopoeia (EP) Reference Standard

别名:

[SP-4-2-(1R-反式)]-(1,2-环己二胺-N,N′)[乙二酸(2-)-O,O’]铂

登录查看组织和合同定价。

选择尺寸

变更视图

关于此项目

经验公式（希尔记法）:

C₈H₁₄N₂O₄Pt

化学文摘社编号:

61825-94-3

分子量:

397.29

NACRES:

NA.24

PubChem Substance ID:

329830895

UNSPSC Code:

41116107

MDL number:

MFCD00866327

技术服务

需要帮助？我们经验丰富的科学家团队随时乐意为您服务。

让我们为您提供帮助

属性

grade

pharmaceutical primary standard

API family

oxaliplatin

manufacturer/tradename

EDQM

application(s)

pharmaceutical (small molecule)

format

neat

storage temp.

2-8°C

SMILES string

O=C1O[Pt]OC1=O.N[C@@H]2CCCC[C@H]2N

InChI

1S/C6H14N2.C2H2O4.Pt/c7-5-3-1-2-4-6(5)8;3-1(4)2(5)6;/h5-6H,1-4,7-8H2;(H,3,4)(H,5,6);/q;;+2/p-2/t5-,6-;;/m1../s1

InChI key

ZROHGHOFXNOHSO-BNTLRKBRSA-L

说明

General description

本品按现行药典规定交付。所有为支持本产品而提供的信息，包括SDS和任何产品信息单均由药典颁发机构制定并发布。如需进一步信息和支持，请访问现行药典网站。

Application

奥沙利铂EP 参考标准品设计用于欧洲药典规定的实验室测试。

Packaging

本品按照现行药典要求提供。有关当前单位数量，请见EDQM 参考目录。

Other Notes

可能适用相应的销售限制。

Still not finding the right product?

Explore all of our products under 奥沙利铂

pictograms

GHS08,GHS05

signalword

Danger

hcodes

H317,H318,H334,H341,H351,H360FD,H362,H372

pcodes

P260 - P263 - P280 - P302 + P352 - P305 + P351 + P338 - P308 + P313

Hazard Classifications

Carc. 2 - Eye Dam. 1 - Lact. - Muta. 2 - Repr. 1B - Resp. Sens. 1B - Skin Sens. 1 - STOT RE 1

存储类别

6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects

wgk

WGK 3

flash_point_f

Not applicable

flash_point_c

Not applicable

历史批次信息供参考:

分析证书(COA)

Lot/Batch Number

It looks like we've run into a problem, but you can still download Certificates of Analysis from our 文件 section.

如需帮助，请联系客户支持

已有该产品？

在文件库中查找您最近购买产品的文档。

访问文档库

Modern multidisciplinary treatment of rectal cancer based on staging with magnetic resonance imaging leads to excellent local control, but distant control remains a challenge.

S M E Engelen et al.

European journal of cancer (Oxford, England : 1990), 49(10), 2311-2320 (2013-04-11)

The purpose of this multicenter cohort study was to evaluate whether a differentiated treatment of primary rectal cancer based on magnetic resonance imaging (MRI) can reduce the number of incomplete resections and local recurrences and improve recurrence-free and overall survival.

Perioperative FOLFOX4 chemotherapy and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC 40983): long-term results of a randomised, controlled, phase 3 trial.

Bernard Nordlinger et al.

The Lancet. Oncology, 14(12), 1208-1215 (2013-10-15)

Previous results of the EORTC intergroup trial 40983 showed that perioperative chemotherapy with FOLFOX4 (folinic acid, fluorouracil, and oxaliplatin) increases progression-free survival (PFS) compared with surgery alone for patients with initially resectable liver metastases from colorectal cancer. Here we present

Epigenetic inactivation of the BRCA1 interactor SRBC and resistance to oxaliplatin in colorectal cancer.

Catia Moutinho et al.

Journal of the National Cancer Institute, 106(1), djt322-djt322 (2013-11-26)

A major problem in cancer chemotherapy is the existence of primary resistance and/or the acquisition of secondary resistance. Many cellular defects contribute to chemoresistance, but epigenetic changes can also be a cause. A DNA methylation microarray was used to identify

查看所有相关文献

全球贸易项目编号

货号	GTIN
Y0000271	04061837568145